Svedberg Karin
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Ophthalmology, Sahlgrenska University Hospital, Region Västra Götaland, Mölndal, Sweden.
Ocul Oncol Pathol. 2023 Feb;8(4-6):236-241. doi: 10.1159/000526985. Epub 2022 Sep 14.
The aim of this study was to investigate the frequency of recurrences, time to recurrence, and which patients had a recurrence after treatment of conjunctival intraepithelial neoplasia (CIN), carcinoma in situ, and primary acquired melanosis (PAM) with atypia.
A retrospective chart review of all patients included in the follow-up program after completion of treatment for CIN or PAM with atypia on October 18, 2021, at the Department of Ophthalmology, Sahlgrenska University Hospital, was conducted.
There were five recurrences (5/31, 17%) in the group with CIN or carcinoma in situ: two for patients with CIN grade II and three for individuals with carcinoma in situ. Time to diagnosis of recurrence ranged from 6 to 288 months. No recurrence was diagnosed for the 26 patients followed after treatment for PAM with atypia.
With the strategy of radical treatment for CIN and PAM with atypia, whenever possible, subsequent follow-up can probably be ceased after 10 years if the patient is not immunocompromised. For completely excised PAM with atypia grade I, there is most likely no need for further clinical controls.
本研究旨在调查结膜上皮内瘤变(CIN)、原位癌和伴有异型性的原发性获得性黑色素沉着症(PAM)治疗后的复发频率、复发时间以及哪些患者会复发。
对2021年10月18日在萨尔格伦斯卡大学医院眼科完成CIN或伴有异型性的PAM治疗后纳入随访计划的所有患者进行回顾性病历审查。
CIN或原位癌组中有5例复发(5/31,17%):2例为CIN II级患者,3例为原位癌患者。复发诊断时间为6至288个月。26例伴有异型性的PAM治疗后随访患者未诊断出复发。
采用对伴有异型性的CIN和PAM进行根治性治疗的策略,只要有可能,如果患者没有免疫功能低下,10年后可能可以停止后续随访。对于完全切除的I级伴有异型性的PAM,很可能无需进一步临床检查。